Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05067283
Title	A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Merck Sharp & Dohme LLC
Indications	colorectal cancer lung non-squamous non-small cell carcinoma Advanced Solid Tumor colorectal adenocarcinoma lung non-small cell carcinoma
Therapies	MK-1084 MK-1084 + Pembrolizumab Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed Disodium Cetuximab + MK-1084 Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| NZL \| ITA \| ISR \| ESP \| DNK \| CHE \| CAN \| AUS